Vaccine Info

Afluria Quadrivalent Influenza Vaccine

Authored by
Staff
Last reviewed
November 15, 2021
Share

Afluria Quadrivalent Influenza Vaccine Description

Seqirus's Afluria Quadrivalent is an inactivated egg-based influenza vaccine designed to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses. AFLURIA QUADRIVALENT is an influenza vaccine for people 6 months and older.

For intramuscular injection only, by needle and syringe (6 months and older) or by PharmaJet® Stratis® Needle-Free Injection System (18 through 64 years); AFLURIA QUADRIVALENT is supplied in 3 product presentations: as a package of ten 0.5-mL prefilled needleless syringes or as a 5-mL multidose vial; Administer AFLURIA QUADRIVALENT as a 0.25-mL dose for patients 6-35 months of age, and as a 0.5-ml dose for patients 36 months of age and older; Both the multidose vial and prefilled syringe presentations are not made with natural rubber latex; The prefilled syringe presentation is preservative-free.

For 2021-2022, the U.S. FDA identified quadrivalent (four-component) egg-based vaccines are recommended to contain: an A/Victoria/2570/2019 (H1N1)pdm09-like virus; an A/Cambodia/e0826360/2020 (H3N2)-like virus; a B/Washington/02/2019 (B/Victoria lineage)-like virus; a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

New Jersey-based Seqirus US is a leader in the fight against influenza with an innovative portfolio of influenza products. As part of the CSL Group, (ASX: CSL; USOTC: CSLLY), Seqirus draws on over a century of experience in influenza vaccines. From 1916 to today, CSL has been driven by the promise to save lives using the latest technologies.

Afluria Quadrivalent Influenza Vaccine Indication

Afluria Quadrivalent is indicated in people 6 months of age and older for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

On July 27, 2021, Gregg Sylvester, M.D., Chief Medical Officer at Seqirus, stated in a press release, “With our rich history and exclusive focus on influenza, we know that influenza vaccination can save lives and is an important step we can take to help protect ourselves, our loved ones and our communities. A continued focus on influenza vaccination is critically important because, while rates of influenza were generally low last season, we cannot assume this will be the case during the coming year, and we need to be prepared."

Afluria Quadrivalent Influenza Vaccine and COVID-19 Vaccines

The US Centers for Disease Control and Prevention previously issued interim clinical considerations stating that 'COVID-19 vaccines and other vaccines, including influenza vaccines, can be administered without regard to timing. And the annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications. 'Providers should be aware of the potential for increased reactogenicity with coadministration and should consult the CDC for updated guidance as more information becomes available. If coadministered, COVID-19 vaccines and vaccines that might be more likely to cause a local reaction (e.g., aIIV4 or HD-IIV4) should be administered in different limbs, if possible.'

'No data are currently available concerning coadministration of currently Authorized COVID-19 vaccines and influenza vaccines,' stated Lisa Grohskopf, M.D., MPH, CDC's ACIP vaccine committee presentation (slide #14) on June 24, 2021.

Afluria Quadrivalent Influenza Vaccine Dosage

Afluria is administered as an intramuscular injection by needle and syringe (6 months+) or by PharmaJet®Stratis® Needle-Free Injection System (18 through 64 years).

Store AFLURIA QUADRIVALENT refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. Discard if the vaccine has been frozen. Do not use it after the expiration date.

Afluria Quadrivalent Influenza Vaccine Side Effects

Afluria Quadrivalent is generally well-tolerated, however, if you or your loved one has an adverse reaction to the vaccine, that information should be reported to VAERS.

VAERS is a U.S. passive reporting system, meaning it relies on individuals to send in reports of their experiences to a vaccine. Anyone can submit a report to VAERS, including parents and patients. Furthermore, healthcare providers are required by law to report to VAERS.

Afluria Quadrivalent Influenza Vaccine News

November 15, 2021 - A phase 4 study in the UK confirmed that vaccination with a COVID-19 vaccine taken at the same time as a flu shot presented no safety concerns.

November 11, 2021 - Based on data up to October 24, the WHO reports that globally influenza activity remains low.

October 16, 2021 - The CDC reported during week 41, 1.8% of patient visits reported through ILINet were due to ILI. This percentage is below the national baseline of 2.5%. Overall, influenza virus circulation remains low; therefore, increases in ILI activity are likely due to increased circulation of other respiratory viruses.

October 7, 2021 - The UK weekly influenza report noted through the Respiratory Datamart 8 influenza-positive samples detected in week 39. Other indicators for influenza such as hospital admissions and GP influenza-like illness consultation rates remain very low.

September 18, 2021 - The CDC reported that the percentages of visits for ILI reported in ILINet are stable or decreasing among all age groups (0-4 years, 5-24 years, 25-49 years, 50-64 years, and 65+ years). Only one region, region 3 was above the baseline of 2.6%.

September 11, 2021 - The US CDC reported three regions are above their region-specific baselines, while the other regions are below their baselines.

September 4, 2021 - Nationwide, the US CDC reported the percentage of patient visits for Influenza-like illness (ILI) remained below the baseline of 2.6% nationally.

August 20, 2021 - The U.S. CDC confirmed during the 2020-2021 flu season in the USA, only (1) influenza-associated pediatric death has occurred. This data contrasts with last flu season, when (198) fatalities were confirmed by the CDC.

August 18, 2021 - The U.S. FDA confirmed (35) Afluria Quadrivalent flu vaccine lots have been released by the FDA and are available for distribution by the manufacturers.

August 18, 2021 - CSL Limited (ASX:CSL; USOTC:CSLLY) announces a reported net profit after tax of $2,375 million for the 12 months ended 30 June 2021, up 13%, or 10% on a constant currency basis.

July 27, 2021 - Seqirus announced that it has begun to ship its portfolio of innovative seasonal influenza vaccines across the U.S. in preparation for the 2021/22 influenza season. 

September 16, 2020 - The American Academy of Pediatrics (AAP) recommends routine influenza immunization of all children without medical contraindications, starting at 6 months of age. Influenza vaccination is an important intervention to protect vulnerable populations and reduce the burden of respiratory illnesses during the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) pandemic. The vaccine formulations available for children 6 through 35 months of age have been updated. Afluria Quadrivalent will be the only vaccine for children 6 through 35 months of age with a dosing volume of 0.25 mL.

July 30, 2020  - Seqirus Begins Shipping 2020/21 Influenza Vaccines to the U.S. Market. "We are collaborating with our partners across the industry to ensure a reliable supply of influenza vaccines throughout the season to help ensure as many eligible people as possible get an influenza vaccination," said Dave Ross, Vice President, North America Commercial Operations at Seqirus. 

Afluria Quadrivalent Influenza Vaccine Clinical Trials

Afluria Quadrivalent has been involved in 12 studies.